
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,600 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 4 January 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 3MB, 218 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
Export 140 results:
[ Author
Filters: First Letter Of Last Name is W [Clear All Filters]
“Prescribing patterns in premenstrual syndrome”, BMC Womens Health, vol. 2, p. 4, 2002.
, “Treatment evolution after COPD diagnosis in the UK primary care setting”, PLoS One, vol. 9, p. e105296, 2014.
, “Respiratory pharmacotherapy use in patients newly diagnosed with chronic obstructive pulmonary disease in a primary care setting in the UK: a retrospective cohort study”, Copd, vol. 11, pp. 521-30, 2014.
, “Evaluation of the General Practice Research Database congenital heart defects prevalence: comparison to United Kingdom national systems”, Birth Defects Res A Clin Mol Teratol, vol. 79, pp. 309-16, 2007.
, “The utility of the general practice research database to examine selected congenital heart defects: a validation study”, Pharmacoepidemiol Drug Saf, vol. 16, pp. 867-77, 2007.
, “Glucocorticoid dose-dependent risk of type 2 diabetes in six immune-mediated inflammatory diseases: a population-based cohort analysis”, BMJ Open Diabetes Res Care, vol. 8, 2020.
, “Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes”, J Clin Oncol, vol. 35, pp. 3647-3653, 2017.
, “Age and sex specific antibiotic prescribing patterns in general practice in England and Wales, 1994 to 1998.”, Health Stat Q, vol. 14, pp. 14-20, 2002.
, “Life Expectancy and Cause-Specific Mortality in Type 2 Diabetes: A Population-Based Cohort Study Quantifying Relationships in Ethnic Subgroups”, Diabetes Care, vol. 40, pp. 338-345, 2017.
, “Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes: A Population-Based Cohort Study Assessing Sex Disparities”, Circulation, 2019.
, “Risk Factor Control and Cardiovascular Event Risk in People With Type 2 Diabetes in Primary and Secondary Prevention Settings”, Circulation, vol. 142, pp. 1925-1936, 2020.
, “Age-, sex- and ethnicity-related differences in body weight, blood pressure, HbA(1c) and lipid levels at the diagnosis of type 2 diabetes relative to people without diabetes”, Diabetologia, 2020.
, “Bisphosphonates and risk of upper gastrointestinal cancer–a case control study using the General Practice Research Database (GPRD)”, PLoS One, vol. 7, p. e47616, 2012.
, “The risk of stillbirth in pregnancies before and after the onset of diabetes”, Diabet Med, vol. 20, pp. 703-7, 2003.
, “Epidemiology of eating disorders in primary care in children and young people: a Clinical Practice Research Datalink study in England”, BMJ Open, vol. 9, p. e026691, 2019.
, “The association between partner bereavement and melanoma: cohort studies in the U.K. and Denmark”, Br J Dermatol, 2020.
, “Partner bereavement and risk of psoriasis and atopic eczema: cohort studies in the United Kingdom and Denmark”, Br J Dermatol, 2019.
, “Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)–a pharmacoepidemiological and qualitative study”, Health Technol Assess, vol. 13, pp. iii-iv, ix-xi, 1-120, 2009.
, “Evaluation of compliance to the timing of childhood vaccinations following introduction of the meningococcal B vaccine in the UK”, Drug Safety, vol. 40, pp. 1000-1, 2017.
, “Benefits of combining prevalent and incident cohorts: An application to myotonic dystrophy”, Stat Methods Med Res, p. 962280218804275, 2018.
, “Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum”, Int J Epidemiol, 2019.
, “Peritonsillar Abscess and Antibiotic Prescribing for Respiratory Infection in Primary Care: A Population-Based Cohort Study and Decision-Analytic Model”, Ann Fam Med, vol. 18, pp. 390-396, 2020.
, “Real world effects of COPD medications: a cohort study with validation against RCT results”, Eur Respir J, 2020.
, “Real-world effects of medications for chronic obstructive pulmonary disease: protocol for a UK population-based non-interventional cohort study with validation against randomised trial results”, BMJ Open, vol. 8, p. e019475, 2018.
, “Development of predictive genetic tests for improving the safety of new medicines: the utilization of routinely collected electronic health records”, Drug Discov Today, vol. 19, pp. 361-6, 2014.
, “Quantification of the risk of liver injury associated with flucloxacillin: a UK population-based cohort study”, J Antimicrob Chemother, vol. 72, pp. 2636-2646, 2017.
, “Optimising case detection within UK electronic health records: use of multiple linked databases for detecting liver injury”, BMJ Open, vol. 6, p. e012102, 2016.
, “No association between exacerbation frequency and stroke in patients with COPD”, Int J Chron Obstruct Pulmon Dis, vol. 11, pp. 217-25, 2016.
, “Suicide risk linked with clinical consultation frequency, psychiatric diagnoses and psychotropic medication prescribing in a national study of primary-care patients”, Psychol Med, vol. 46, pp. 3407-3417, 2016.
, “Antibiotic prescribing and outcomes of lower respiratory tract infection in UK primary care”, Chest, vol. 135, pp. 1163-1172, 2009.
, “Lithium use and the risk of fractures”, Bone, vol. 40, pp. 1252-8, 2007.
, “Financial incentives improve recognition but not treatment of cardiovascular risk factors in severe mental illness”, PLoS One, vol. 12, p. e0179392, 2017.
, “Previously diagnosed influenza infections and the risk of developing epilepsy”, Epidemiol Infect, vol. 143, pp. 2408-15, 2015.
, “Incidence and risk of glucocorticoid-associated adverse effects in patients with rheumatoid arthritis”, Arthritis Care Res (Hoboken), 2018.
, “Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis”, Semin Arthritis Rheum, vol. 46, pp. 650-656, 2017.
, “Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis”, Semin Arthritis Rheum, vol. 46, pp. 819-827, 2017.
, “Inflammatory Bowel Disease and the Risk of Autoimmune Diseases”, J Crohns Colitis, vol. 10, pp. 186-93, 2016.
, “A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease”, J Gastroenterol, vol. 51, pp. 1050-1062, 2016.
, “Non-steroidal anti-inflammatory drug use and cervical cancer risk: a case-control study using the Clinical Practice Research Datalink”, Cancer Epidemiol, vol. 37, pp. 897-904, 2013.
, “Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the General Practice Research Database”, Cancer Epidemiol, vol. 38, pp. 544-9, 2014.
, , “Consultations for middle ear disease, antibiotic prescribing and risk factors for reattendance: a case-linked cohort study”, Br J Gen Pract, vol. 56, pp. 170-5, 2006.
, “Cancer recording in patients with and without type 2 diabetes in the Clinical Practice Research Datalink primary care data and linked hospital admission data: a cohort study”, BMJ Open, vol. 8, p. e020827, 2018.
, “Cardiovascular safety of vildagliptin in patients with type 2 diabetes: A European multi-database, non-interventional post-authorization safety study”, Diabetes Obes Metab, vol. 19, pp. 1473-1478, 2017.
, “Pancreatic safety of vildagliptin in patients with type 2 diabetes mellitus: A European, noninterventional, postauthorization safety study”, Endocrinol Diabetes Metab, vol. 2, p. e00052, 2019.
, “Association between vildagliptin and risk of angioedema, foot ulcers, skin lesions, hepatic toxicity, and serious infections in patients with type 2 diabetes mellitus: A European multidatabase, noninterventional, postauthorization safety study”, Endocrinol Diabetes Metab, vol. 2, p. e00084, 2019.
, “Psychiatric and cardiovascular comorbidities in patients with diabetes mellitus starting antiobesity drugs”, Obesity (Silver Spring), vol. 16, pp. 2331-5, 2008.
, “Importance of feasibility assessments before implementing non-interventional pharmacoepidemiologic studies of vaccines: lessons learned and recommendations for future studies”, Pharmacoepidemiol Drug Saf, vol. 25, pp. 1397-1406, 2016.
, “Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom”, Hum Vaccin Immunother, vol. 12, pp. 2862-2871, 2016.
, “Changing use of antidiabetic drugs in the UK: trends in prescribing 2000-2017”, BMJ Open, vol. 8, p. e022768, 2018.
,